128 related articles for article (PubMed ID: 16377955)
1. Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.
Makino K; Kochi M; Nakamura H; Kuroda J; Honda Y; Ushio Y; Kuratsu J
Neurol Med Chir (Tokyo); 2005 Dec; 45(12):650-2. PubMed ID: 16377955
[TBL] [Abstract][Full Text] [Related]
2. Studies on adsorption characteristics of bile acids and methotrexate to a new type of anion-exchange resin, colestimide.
Honda Y; Nakano M
Chem Pharm Bull (Tokyo); 2000 Jul; 48(7):978-81. PubMed ID: 10923826
[TBL] [Abstract][Full Text] [Related]
3. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
Urata S; Yoshikawa N; Saito K; Tazaki T; Ohno R; Takeshima H; Ikeda R
J Clin Pharm Ther; 2021 Dec; 46(6):1796-1799. PubMed ID: 34008211
[TBL] [Abstract][Full Text] [Related]
4. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
[TBL] [Abstract][Full Text] [Related]
7. Carboxypeptidase G2 rescue after high-dose methotrexate.
DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
[TBL] [Abstract][Full Text] [Related]
8. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
[TBL] [Abstract][Full Text] [Related]
9. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
10. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
Ferreri AJ; Guerra E; Regazzi M; Pasini F; Ambrosetti A; Pivnik A; Gubkin A; Calderoni A; Spina M; Brandes A; Ferrarese F; Rognone A; Govi S; Dell'Oro S; Locatelli M; Villa E; Reni M
Br J Cancer; 2004 Jan; 90(2):353-8. PubMed ID: 14735176
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.
Mei S; Li X; Jiang X; Yu K; Lin S; Zhao Z
J Pharm Sci; 2018 May; 107(5):1454-1460. PubMed ID: 29331383
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
14. in vitro- and in vivo Evaluation of Methotrexate-Loaded Hydrogel Nanoparticles Intended to Treat Primary CNS Lymphoma via Intranasal Administration.
Pourtalebi Jahromi L; Mohammadi-Samani S; Heidari R; Azadi A
J Pharm Pharm Sci; 2018; 21(1):305-317. PubMed ID: 30053381
[TBL] [Abstract][Full Text] [Related]
15. [II. Primary treatment of CNS lymphoma with high-dose MTX].
Iwadate Y
Gan To Kagaku Ryoho; 2012 Jun; 39(6):892-7. PubMed ID: 22880222
[No Abstract] [Full Text] [Related]
16. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
17. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.
Joerger M; Huitema AD; Illerhaus G; Ferreri AJ
Leuk Lymphoma; 2012 Oct; 53(10):1867-75. PubMed ID: 22530664
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
[TBL] [Abstract][Full Text] [Related]
19. Colestimide reduces blood polychlorinated biphenyl (PCB) levels.
Sakurai K; Fukata H; Todaka E; Saito Y; Bujo H; Mori C
Intern Med; 2006; 45(5):327-8. PubMed ID: 16596004
[No Abstract] [Full Text] [Related]
20. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]